- Home
- » Tags
- » Rociletinib
Top View
- Your Guide to the Latest Cancer Research and Treatments
- Clinical Development of Targeted and Immune Based Anti-Cancer Therapies N
- The Use of Superlatives in Cancer Research
- Utilizing Chemoproteomic Platforms to Elucidate Toxicological Mechanisms
- Emerging Therapies for Non-Small Cell Lung Cancer Chao Zhang1,3, Natasha B
- Status of Genetic Modulated Nonsmall Cell Lung Cancer Targets and Treatment (Current Updates in Drugs for Non-Small Cell Lung Cancer Treatment)
- Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer
- Circulating Tumor Cells in Lung Cancer Are Prognostic and Predictive for Worse Tumor Response in Both Targeted- and Chemotherapy
- KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
- A Comparison Between First-, Second- and Third-Generation Epidermal
- Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in T790M-Positive Non-Small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance
- HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Changelog (In Alphabetical Order of the Value Set) Value Set Code Description Change
- Peerview.Com/NPG900 Education
- Endocrine-Metabolic Effects of Treatment with Multikinase Inhibitors
- Molecular Dynamics Simulation-Guided Drug Sensitivity Prediction for Lung Cancer with Rare EGFR Mutations
- Download Article (PDF)
- Rociletinib for Advanced Or Recurrent Non-Small Cell Lung Cancer with the EGFR T790M Mutation
- United States Securities and Exchange Commission Form
- Xegafri, INN-Rociletinib
- FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer
- Third Generation EGFR Tkis
- KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
- Egfr) Non-Small Cell Lung Cancer (Nsclc)
- 82846611.Pdf
- The Systemic Exclusion of Native Americans from Cancer Clinical Trials
- Sonny P. Medina, Et Al. V. Clovis Oncology, Inc., Et Al. 15-CV-02546
- Management of Hyperglycemia from Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (Tkis) Targeting T790M- Mediated Resistance
- Preclinical Comparison of Osimertinib with Other EGFR-Tkis in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of C
- Staying One Step Ahead of Lung Cancer Jane De Lartigue, Phd
- Tyrosine Kinase Inhibitors Enhanced the Efficacy of Conventional Chemotherapeutic Agent in Multidrug Resistant Cancer Cells Shaocong Wu and Liwu Fu*
- Xegafri, INN-Rociletinib
- A Phase 1B/2 Study of the Safety and Efficacy of Rociletinib (CO-1686)
- Molecular Imaging in Cancer Drug Development
- Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective
- Clovis Oncology Announces Rociletinib New Drug Application Scheduled for Presentation at Upcoming FDA Oncologic Drugs Advisory Committee Meeting
- Shivangi Awasthi
- Biological Therapies in Nonsmall Cell Lung Cancer
- Supplementary Table 3
- Third-Generation Inhibitors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer Shuhang Wang1, Shundong Cang2 and Delong Liu3,4*